Under the pact, Pfenex will engineer production strains and develop early production processes for MedImmune‘s proprietary molecules.
The tie up also allows MedImmune to carry forward the preclinical and clinical development for these molecules to progress quickly and efficiently.
Pfenex is eligible to get an annual technology access fees, FTE resource funding from MedImmune.
Pfenex CEO Bertrand Liang said the partnership will facilitate speed and reliability in the development of protein therapeutics and vaccines to serve unmet medical needs.
MedImmune Biopharmaceutical Development senior vice president Gail Wasserman said Pfenex’s scientific approach to strain development and protein expression is robust and aligned with the way they work at the company.